Add categories

Browse categories and add by clicking on them

You can remove current categories below by clicking the ‘x’.


watsoncraig
2 weeks ago

Fingers crossed. 188 could become my favourite number


dominics
2 weeks ago

It certainly looks encouraging.
– Not to pee on the parade but that is not even final endpoint data. The trial – https://clinicaltrials.gov/ct2/show/NCT03283826 – is 97 people and Phase 1 so just testing for safety. Most biotech companies are a VC funded as it is a high (financial) risk high reward game. Any crumbs of positivity are seized upon to show the investors why they need to keep ploughing money in.

If it turns out as a ‘good thing’ and fingers crossed that it does the firm will either be bought in whole or sell the rights to the product to a large pharma company with the financial and marketing muscle to bring it to market.

This trial ends earliest Set 2022. Then Phase 2 trials to show efficacy and if so then expanded big numbers high cost phase 3 trials before getting a license.

I’d be keeping an eye on things and be making it very clear to the nearest clinical trial centre to you that the moment it goes to a Phase 2 trial and assuming they are involved then you’d like to get signed up.

Time to market from now if everything works out perfectly and they get accelerated licensing is c. 2028.


dominics
2 weeks ago

stumbler
2 weeks ago

@john_barry , that was huge. I’ve not seen a weblink that big for ages! 🤣🤣🤣

It does sound very encouraging, but clinical trials go on forever……😥


john_barry
2 weeks ago

@dominics Excellent link, thanks. I was hoping for 2024 or 2025, but I’ve been waiting for an effective therapy for more than 30 yrs now, so an extra few years seems ok (I’m not holding my breath).


dominics
2 weeks ago

@john_barry pharmaceutical development is achingly and frustratingly slow. Why I suggest getting on to the Phase 2 trial if the safety data from Phase 1 is good.

Let me know if interested. I’ll help you understand how – in general terms – to go about it.

Join Shift.ms to reply to this post.

Become part of the community so you can chat, compare and learn from other MSers.